Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC.

Objective: NMK36 is a novel PET tracer containing a synthetic amino acid analogue anti-[(18)F]FACBC as the active ingredient, and is under development for the use of tumor diagnosis. A Phase I clinical study of NMK36 was conducted to evaluate its safety, biodistribution, and radiation dosimetry in healthy volunteers.

Methods: Six healthy volunteers (Japanese male) received a bolus injection of NMK36 (174.